Scientific deep-dive
ATTAIN-MAINTAIN: Can a Pill Hold Weight Loss After Injections?
In a one-year trial, people who switched from tirzepatide or semaglutide to daily orforglipron kept more of their weight loss than those on placebo. No group stayed on the injection, so it can’t show whether the pill does as well as continuing it.
Compared with a switch to placebo, a daily pill held on to more of the weight lost on an injection. In ATTAIN-MAINTAIN, people who moved from tirzepatide to orforglipron kept a model-estimated 74.7% of their earlier loss at week 52, against 49.2% on placebo; after semaglutide the figures were 79.3% and 37.6% (treatment-regimen estimand, participants at a weight plateau).[1] The trial can’t say whether the pill holds weight as well as staying on the injection, because no group continued injections.[1]
About this article
This page covers the outcomes of the maintenance trial, read from its full text in Nature Medicine. For how the Foundayo and Zepbound labels handle doses, see our guide to switching between the two.
Who was in the trial
Everyone came from SURMOUNT-5, the head-to-head trial in which 72 weeks of tirzepatide produced a mean weight change of −20.2%, compared with −13.7% on semaglutide.[2] To enter ATTAIN-MAINTAIN, participants had to finish SURMOUNT-5 on treatment with at least a 5% weight reduction, and people with diabetes were excluded.[1] That left 376 adults at 29 US sites: 205 from the tirzepatide group and 171 from the semaglutide group, randomized 3:2 to orforglipron or placebo and analyzed as two separate cohorts.[1] The sponsor, Eli Lilly, makes both orforglipron and tirzepatide.[1]
The first blinded dose was meant to come within 14 days of the last injection. Participants skipped the low starting doses and began at a 12 mg capsule (equivalent to the 9 mg tablet sold in the US), then stepped up every 4 weeks to the 36 mg capsule (17.2 mg tablet) or the highest dose they could tolerate.[1] Everyone received lifestyle counseling.[1]
The week 52 results
The primary measure is unusual: the share of the SURMOUNT-5 weight loss still present at week 52, as a model-based estimate, in people whose weight had plateaued (less than 5% change over weeks 60 to 72). All numbers in this table use the modified treatment-regimen estimand, which counts people whether or not they stayed on their assigned treatment.[1]
| Measure | After tirzepatide | After semaglutide |
|---|---|---|
| Weight loss maintained, plateau group (primary) | 74.7% vs 49.2%; difference 25.5 (95% CI 14.5 to 36.5) | 79.3% vs 37.6%; difference 41.7 (95% CI 24.4 to 59.0) |
| Kept at least 80% of the loss, plateau group | 43.7% vs 16.4% | 55.0% vs 6.9% |
| Weight loss maintained, all participants | 74.4% vs 49.7% | 85.9% vs 40.2% |
| Weight change from SURMOUNT-5 start, all participants | −16.5% vs −12.6%; difference −3.9 points | −14.9% vs −7.9%; difference −7.0 points |
All of those comparisons reached P<0.001.[1] The two cohorts were analyzed separately, so the gap between the columns isn’t a tested comparison of the two injectables. The authors had expected more regain coming off a dual GIP/GLP-1 drug than off a GLP-1 drug, and they say this needs further study.[1]
What that looks like in kilograms
Percentages of a percentage are hard to picture, so the authors added a sensitivity analysis of absolute weight. It uses the efficacy estimand, which assumes people stayed on treatment, and it covers only the orforglipron groups.[1]
- After tirzepatide: 115.8 kg at the start of SURMOUNT-5, 90.9 kg when the switch happened, 95.9 kg at week 52. That is a regain of about 5 kg, leaving a 16.8% reduction from the original weight.[1]
- After semaglutide: 113.5 kg, then 95.0 kg, then 95.9 kg. That is about 1 kg of regain, leaving a 15.1% reduction.[1]
- Keeping a 15% loss: among those who had reached at least 15% in SURMOUNT-5, 63.7% (tirzepatide cohort) and 69.5% (semaglutide cohort) still had it at week 52.[1]
Waist size moved the same way, up about 3 cm after tirzepatide and about 1 cm after semaglutide. Mean HbA1c stayed at 5.2% in both groups, though these participants did not have diabetes and began SURMOUNT-5 at 5.6%.[1] Both cohorts ending at exactly 95.9 kg led the authors to float a possible biological set point. They present that as an idea for further study, and it isn’t something this trial tested.[1]
Why the placebo group is hard to read
From week 24, anyone on placebo who regained 50% or more of the earlier loss could start orforglipron as rescue. Rescue went to 39 placebo participants in the tirzepatide cohort and 42 in the semaglutide cohort, and others left to start approved obesity drugs. By week 52 only 25 people (31.3%) and 12 people (18.2%) had stayed on placebo with no active treatment.[1] The authors say this design doesn’t allow a pure placebo comparison after week 24, and that the small numbers made the percent-maintained measure quite variable.[1]
So the placebo column is not a clean picture of coming off treatment. Withdrawal trials get closer to that: weight rose 14.0% over 52 weeks after people were switched from tirzepatide to placebo in SURMOUNT-4, and 6.9% over 48 weeks after the switch from semaglutide in STEP 4.[3][4] Our review of weight regain after stopping tirzepatide goes further into that data. A 2026 systematic review of stopping GLP-1-based drugs, which searched the literature through September 2026, still called the evidence for pharmacologic transition strategies limited.[6]
Does the pill match staying on the injection?
This trial can’t answer that, and the authors list the missing continued-injection arm as a limitation, along with the one-year length and the US-only sites.[1] It’s tempting to borrow from SURMOUNT-4, where 89.5% of people who stayed on tirzepatide kept at least 80% of their lead-in loss.[3] That figure doesn’t line up with the table above. SURMOUNT-4 randomized people at week 36, not week 72, and its abstract doesn’t name the estimand behind that number.[3]
There is one cross-trial detail worth noting, with a caveat. In ATTAIN-1, the 36 mg capsule produced −11.2% at week 72 under the treatment-regimen estimand, in people starting from scratch.[5] The orforglipron groups here sat at a numerically larger −16.5% and −14.9%, under a modified version of that estimand.[1] That hints the pill may hold more weight than it would have taken off on its own. But these participants were selected: they had finished 72 weeks of injections and had already responded and tolerated treatment, so the result may not carry over to someone leaving an injection because of side effects or a poor response.
Side effects after the switch
The table covers the period before any rescue treatment. Nausea was the standout in the tirzepatide cohort, and constipation in the semaglutide cohort.[1]
| Event | After tirzepatide: orforglipron (n=124) | After tirzepatide: placebo (n=80) | After semaglutide: orforglipron (n=105) | After semaglutide: placebo (n=66) |
|---|---|---|---|---|
| Nausea | 23.4 | 5.0 | 13.3 | 3.0 |
| Vomiting | 11.3 | 1.2 | 4.8 | 6.1 |
| Constipation | 12.1 | 5.0 | 14.3 | 3.0 |
| Diarrhea | 7.3 | 11.2 | 7.6 | 3.0 |
| Serious adverse events | 2.4 | 0 | 1.0 | 1.5 |
| Stopped treatment because of an adverse event | 7.3 | 2.5 | 4.8 | 3.0 |
Moving straight to the 12 mg capsule went fairly smoothly. No one needed a dose reduction in the first 4 weeks, and the results section puts gastrointestinal events in that window at 10.5% and 9.5% of the two cohorts, although the discussion section gives a lower figure of fewer than 5%.[1] One case of mild pancreatitis was confirmed in the tirzepatide cohort, and one death on orforglipron (recorded as cardiovascular/stroke) was judged unrelated to treatment. ALT reached three times the upper limit of normal in four orforglipron participants in the tirzepatide cohort, one in the semaglutide cohort, and one on placebo in each cohort; the authors reported no liver safety signal.[1] With 230 people randomized to orforglipron (229 of them in the safety table above) over one year,[1] this trial can’t rule out uncommon harms.
The starting dosage is 0.8 mg orally once daily.— Foundayo prescribing information, section 2
That label instruction differs from the trial’s starting point. The label’s dosing section doesn’t describe a transition from an injectable GLP-1, and it states that “Concomitant use with another GLP-1 receptor agonist is not recommended.”[7] The trial’s authors say their data support the 12 mg capsule as a starting dose after injectables, but that is their reading of one trial and not label language.[1]
What to raise with a prescriber
- Why you want to leave the injection. The trial tested people who were doing well on treatment, not people who stopped because it wasn’t working or wasn’t tolerated.
- How much regain you would accept. On average about 5 kg came back after tirzepatide and about 1 kg after semaglutide, and individuals varied.[1]
- What dose to start on, given the difference between the trial and the label, and how soon after your last injection.
- What you will do if weight climbs, including when to reconsider an injectable, since the trial has no data past one year.[1]
Frequently Asked Questions
References
- 1.Aronne LJ, Horn DB, le Roux CW, Chao AM, Ho W, Halpern B, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. PMID: 42120723.
- 2.Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. PMID: 40353578.
- 3.Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID: 38078870.
- 4.Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. PMID: 33755728.
- 5.Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025. PMID: 40960239.
- 6.Marchetti M, Campisano G, Paragliola RM, Francomano D, Cipolloni V, Conforti A. Weight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review. Metabolites. 2026. PMID: 42941232.
- 7.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, for oral use: US Prescribing Information. DailyMed (NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
Related research
SURMOUNT-MAINTAIN: Can You Step Down Tirzepatide and Keep the Loss?
A randomized Lancet trial tested stepping tirzepatide down to 5 mg after 60 weeks at full dose. It kept more weight off than placebo and less than staying on full dose, and a quarter of people received rescue treatment.
7 min read
ATTAIN: Oral Orforglipron for Obesity (2026)
ATTAIN-1 deep-dive: oral orforglipron drove 11.2% average weight loss over 72 weeks in obesity without diabetes, 54.6% reached 10%, taken as a no-restriction daily pill.
13 min read
Orforglipron vs Rybelsus: How the Two Oral GLP-1 Pills Compare (2026)
Orforglipron (Foundayo) vs Rybelsus (oral semaglutide): a 2026 head-to-head on molecule type, indication, how you take each, effectiveness, cost, and side effects — and who should pick which.
9 min read
Is Orforglipron Safe for the Liver? The Pooled Phase 3 Data
A Lilly-funded pooled analysis of seven phase 3 trials found no confirmed Hy's Law cases with orforglipron. What it measured, where numbers ran higher, who was excluded, and what FDA asked Lilly to keep tracking after approval.
8 min read
Orforglipron and the Heart: The Lancet Cardiovascular Safety Trial
ACHIEVE-4 found orforglipron non-inferior to insulin glargine for major cardiovascular events in high-risk adults with type 2 diabetes. What the result shows, what it leaves open, and how far it applies to people taking Foundayo for weight.
8 min read
Oral vs Injectable GLP-1: Cost, Effectiveness & How to Choose (2026)
Oral GLP-1 pills (Foundayo/orforglipron, Rybelsus) vs injectable semaglutide and tirzepatide — compared on cost, average weight loss, dosing and food rules, with a clear who-should-choose-which.
9 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Oak
Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up
Read full review →From $200/mo
starting dose
From $99/mo
From $139/mo
4-month plan rate